Clinical Trials in Overt Diabetic Nephropathy

  • Staffan Björck

Abstract

There is only limited data available regarding how overt diabetic nephropathy should be treated to arrest the progressive decline in renal function. There is agreement on that antihypertensive treatment should be aggressive and that ACE-inhibitors offers an advantage but other interventions, such as improved metabolic control is still controversial. In non-diabetic renal disease, intensive antihypertensive treatment adds only little benefit [1]. In contrast to this, several studies have shown that aggressive antihypertensive treatment is probably the most important factor to determine the rate of decline in kidney function in diabetic nephropathy. The evidence that antihypertensive treatment can preserve renal function is based on the much reduced rate of renal disease progression after effective blood pressure control [2,3]. These studies compare the rate of decline in glomerular filtration rate during intervention with retrospective data. This is not ideal since uncontrolled factors might influence the outcome. However, the effect of antihypertensive treatment is so profound that it is obviously very important for the kidney in diabetic nephropathy. Anyone that treats these patients observe that end-stage renal failure is postponed by antihypertensive treatment and that the disease runs an accelerated course during uncontrolled hypertension. It is a generally held opinion that once established, overt diabetic nephropathy does not benefit from more intense blood-glucose control.

Keywords

Glomerular Filtration Rate Diabetic Nephropathy Angiotensin Converting Enzyme Antihypertensive Treatment Nocturnal Blood Pressure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effect of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1993; 330: 877–874.CrossRefGoogle Scholar
  2. 2.
    Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 1987; 294: 1443–1447.PubMedCrossRefGoogle Scholar
  3. 3.
    Mogensen CE. Progression of nephropathy in long-term diabetics with proteinuria and effect of initial anti-hypertensive treatment. Scand J Clin Lab Invest 1976; 36: 383–388.PubMedCrossRefGoogle Scholar
  4. 4.
    Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M: Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 1986; 293: 467–470.CrossRefGoogle Scholar
  5. 5.
    Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.PubMedCrossRefGoogle Scholar
  6. 6.
    Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y: Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313: 1617–1620.PubMedCrossRefGoogle Scholar
  7. 7.
    Rudberg S, Aperia A, Freyschuss U, Persson B. Enalapril reduces microalbuminuria in young normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia 1990; 33: 470–476.PubMedCrossRefGoogle Scholar
  8. 8.
    Elving LD, Wetzels JFM, de Nobel E, Hoitsma AJ, Berden JHM. Captopril acutely lowers albuminuria in normotensive patients with diabetic nephropathy. Am J Kidney Dis 1992; 20: 559–563.PubMedGoogle Scholar
  9. 9.
    Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection, Kidney Int 1992; 41: 912–919.CrossRefGoogle Scholar
  10. 10.
    Holdaas H, Hartmann A, Lien MG, Nilsen L, Jervell J, Fachald P, Endresen L, Djøseland O, Berg KJ. Contrasting effects of lisinopril and nifidepine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Int Med 1991; 229: 163–170.CrossRefGoogle Scholar
  11. 11.
    Gansevoort RT, Apperloo AJ, Heeg JE, De Jong PE, De Zeeuw D. The antiproteinuric effect of antihypertensive agents in diabetic nephropathy. Arch Int Med 1992; 152: 2137–2138.CrossRefGoogle Scholar
  12. 12.
    Björck S, Mulec H, Johnsen SA, Nordén G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339–343.PubMedCrossRefGoogle Scholar
  13. 13.
    Stornello M, Valvo EV, Scapellato L. Comparative effects of enalapril, atenolol and chlorothalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. Nephron 1991; 58: 52–57.PubMedCrossRefGoogle Scholar
  14. 14.
    Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Int Med 1993; 118: 129–138.PubMedCrossRefGoogle Scholar
  15. 15.
    Mulec H, Johnsen S-A, Björck S. Long-term enalapril treatment in diabetic nephropathy. Kidney Int 1994; 45: Suppl. 45: S–141–S–144.Google Scholar
  16. 16.
    Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decreaseatrialnatriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. Am J Hypertens 1992.Google Scholar
  17. 17.
    Ferder L Daccordi H, Panzalis M, Inserra F. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992; 19: Suppl. 2: II–237–II–242.Google Scholar
  18. 18.
    Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Int Med 1993; 118: 577–581.PubMedCrossRefGoogle Scholar
  19. 19.
    The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.CrossRefGoogle Scholar
  20. 20.
    Microalbuminuria collaborative study group: Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 1995; 311: 973–977.CrossRefGoogle Scholar
  21. 21.
    Krolewski AS, LMB Lafel, Krolewski M, Quinn M and Warram JH. Glycosylated haemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 332: 1251–1255.PubMedCrossRefGoogle Scholar
  22. 22.
    Mulec H, Blohmé G, Kullenberg K, Nyberg G, Björck S. Latent overhydration and nocturnal hypertension in diabetic nephropathy. Diabetologia 1995; 38: 216–220.PubMedCrossRefGoogle Scholar
  23. 23.
    Heeg JE, De Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272–279.PubMedCrossRefGoogle Scholar
  24. 24.
    Maschio G, Alberti D, Janin G, Locatelli F, Mann JFE, Motolese M, Ponticelli C, Ritz E, Zucchelli P, the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. Effect of angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996; 334: 939–945.PubMedCrossRefGoogle Scholar
  25. 25.
    Bennet PH, Haffner S, Kasiske BL, Keane WF, Mogensen CE, Parving H-H, Steffes MW, Striker GE. Diabetic renal disease recommendations. Am J Kidney Dis 1995; 25: 107–112.CrossRefGoogle Scholar
  26. 26.
    Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving H-H, Passa P, Steffes MW, Striker GE, Viberti GC. Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 1995; 346: 1080–1084.PubMedCrossRefGoogle Scholar
  27. 27.
    Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403–1407.PubMedCrossRefGoogle Scholar
  28. 28.
    Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving H-H. Impact of Nisoldipine and Lisonopril on kidney function in hypertensive IDDM subjects with diabetic nephropathy (Abstract). Diabetologia 1996; 39: Suppl. 1: A308.Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Staffan Björck
    • 1
  1. 1.Njurmottagningen, Sahlgrenska sjukhusetGöteborgSverige

Personalised recommendations